所有图片(1)

文件

1359404

USP

左乙拉西坦

Name: 左乙拉西坦
Brand: USP

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价

所有图片(1)

别名:

(αS)-α-乙基-2-氧代-1-吡咯烷乙酰胺, 2（S）-（2-氧吡咯烷-1-基）丁酰胺, Keppra^®

经验公式（希尔记法）:

C₈H₁₄N₂O₂

CAS号:

102767-28-2

分子量:

170.21

MDL编号:

MFCD03265610

PubChem化学物质编号:

329750033

NACRES:

NA.24

等级

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

格式

neat

SMILES string

CC[C@H](N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

InChI key

HPHUVLMMVZITSG-LURJTMIESA-N

Gene Information

human ... CACNA1B(774) , SV2A(9900)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Levetiracetam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

生化/生理作用

左乙拉西坦是一种具有抗癫痫活性的吡咯烷。左乙拉西坦的立体选择性结合仅限于中枢神经系统的突触质膜，而在周围组织中不发生立体选择性结合。左乙拉西坦在不影响正常神经元兴奋性的情况下抑制簇状放电，这表明它可以选择性地阻止癫痫样簇状放电的超同步和发作活动的传播。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

其他说明

Sales restrictions may apply.

警示用语：

Warning

危险声明

H302 - H319

预防措施声明

P264 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313 - P501

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review.

Johan Zelano et al.

Seizure, 21(4), 233-236 (2012-02-11)

The role of new antiepileptic drugs (AED) in the treatment of status epilepticus (SE) is of interest, especially in benzodiazepine-resistant status epilepticus where phenytoin is deemed inappropriate due to allergy or comorbidity. Levetiracetam (LEV) is a new AED with few

A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures.

Justin B Usery et al.

Journal of neuro-oncology, 99(2), 251-260 (2010-02-11)

To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection. Brain tumor patients undergoing neurosurgery with >or=1 seizure within the preceding month prior to surgery were enrolled to receive intravenous

[Experience with levetiracetam in the treatment of status epilepticus].

J Rösche et al.

Fortschritte der Neurologie-Psychiatrie, 81(1), 21-27 (2012-08-15)

Non-convulsive status epilepticus and epilepsia partialis continua are common epileptic conditions for which straightforward recommendations based on controlled randomised trials for treatment of therapy refractory courses are lacking. Therefore in these conditions sometimes antiepileptic drugs that are not approved by

Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.

Rafal M Kaminski et al.

Epilepsia, 50(3), 387-397 (2008-07-17)

Levetiracetam (Keppra) is an antiepileptic drug (AED) characterized by a novel mechanism of action, unique profile of activity in seizure models, and broad-spectrum clinical efficacy. The present report critically reviews several preclinical studies focused on combination therapy with levetiracetam and

Levetiracetam: a review of its use in epilepsy.

Katherine A Lyseng-Williamson

Drugs, 71(4), 489-514 (2011-03-15)

Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizures with

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件